In patients in whom the major therapeutic goal is the compelling need to minimize the therapeutic risk pf hypoglycaemia, DPP-4 inhibitors are recommended as second line therapy after metformin failure at the same level as second line treatment options with GLP-1 receptor agonists, SGLT-2 inhibitors, or TZDs
Extended exposure (more than a day in warm temperatures): Likely degrades potency
Nous y rpondons en 5 points
One of our pharmacists will be happy to answer your questions, discuss compounding options, and help you better understand your prescription
How Is IV Therapy Different From Oral Supplements
Meanwhile, both Eli Lily and NovoNordisk recently asked the FDA to ban compounded copies of their drugs, saying they are too complex to safely produce